Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas

Hohaus, Stefan; Giachelia, Manuela; Massini, Giuseppina; Mansueto, Giovanna; Vannata, Barbara; Bozzoli, Valentina; Criscuolo, Marianna; D’Alo’, Francesco; Martini, Maurizio; Larocca, Luigi Maria; Voso, Maria Teresa; Leone, Giuseppe

doi:10.1093/annonc/mdp006

Cited by 124 publications

(129 citation statements)

References 22 publications

Supporting

Mentioning

109

Contrasting

Unclassified

Order By: Relevance

“…8,9 Patients with cancer have higher overall levels of cfDNA than healthy people, but the fraction of DNA from malignant cells, captured as ctDNA, may be as low as 0.01%. [10][11][12] Because ctDNA derives from tumor tissue, it is a highly specific tumor biomarker. 13 It is present without detectable circulating tumor cells and correlates with tumor burden in early-and late-stage malignancies.…”

Section: Technical Aspects Of Ctdnamentioning

confidence: 99%

Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma

Roschewski

Staudt

Wilson

2016

Blood

View full text Add to dashboard Cite

Response assessment in lymphoma relies on imaging scans that do not capture biologic processes at the molecular level. Monitoring circulating tumor DNA (ctDNA) with next-generation sequencing–based assays can detect recurrent disease prior to scans and “liquid biopsies” for somatic mutations address tumor heterogeneity, clonal evolution, and mechanisms of resistance to guide precision treatment. Preanalytic collection and processing procedures should be validated and standardized. We describe emerging applications of ctDNA monitoring including real-time analysis of tumor dynamics, preclinical disease detection, and precision-directed treatment paradigms.

show abstract

Section: Technical Aspects Of Ctdnamentioning

confidence: 99%

Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma

Roschewski

Staudt

Wilson

2016

Blood

View full text Add to dashboard Cite

show abstract

“…In a large cohort of cases of Hodgkin lymphoma, mantle cell lymphoma and DLBCL, increased levels of plasma DNA (determined using quantitative polymerase chain reaction for the b-globin gene) were associated with advanced stage disease, presence of B-symptoms, elevated lactate dehydrogenase levels, and age >60 years also indicating that the amount of circulating DNA is partially related to tumor burden. 8 Furthermore, it was shown in a cohort of patients with Epstein-Barr virus-positive lymphoma that serum and plasma were equivalent for detecting lymphoma-specific DNA but that only the lymphomaspecific DNA could be used to monitor disease response in lymphoma.…”

Section: -8mentioning

confidence: 99%

Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis

et al. 2015

View full text Add to dashboard Cite

“…(12) In contrast, the circulating DNA level is a strong and independent prognostic predictor in Hodgkin's lymphoma and non-Hodgkin's lymphoma. (13) Recently, the circulating DNA level has been quantified with a real-time quantitative PCR method for estimating its diagnostic or prognostic value in early breast cancer patients. (14) This work investigated the correlation of the UHRF1 DNA level in plasma with clinical characteristics of breast cancer and its clinical significance in breast cancer diagnosis.…”

mentioning

confidence: 99%

Diagnostic and prognostic value of plasma and tissue ubiquitin‐like, containing PHD and RING finger domains 1 in breast cancer patients

Geng

Gao

et al. 2012

Cancer Science

View full text Add to dashboard Cite

Ubiquitin-like, containing PHD and RING finger domains 1 (UHRF1) has been reported to play an important role in breast carcinogenesis. This work investigated the correlation of UHRF1 DNA level in plasma with clinical characteristics of breast cancer and its clinical significance in breast cancer diagnosis. The expression of UHRF1 in primary breast cancer tissue was examined by Western blot. The UHRF1 DNA levels in plasma and UHRF1 mRNA expression in tissues were determined by accurate real-time quantitative PCR. The associations of UHRF1 levels with clinical variables were evaluated using standard statistical methods. The UHRF1 DNA in plasma of 229 breast cancer patients showed higher expression than healthy controls, which showed high specificity up to 76.2% at a sensitivity of 79.2%, and was significantly associated with c-erbB2 positive status, cancer stage and lymph node metastasis. High UHRF1 DNA level in plasma was significantly associated with short progression-free survival. The UHRF1 DNA level in plasma is highly correlative with breast cancer and its status and stage, and may be a potential independent diagnostic and prognostic factor for both breast cancer and the survival of breast cancer patients. (Cancer Sci 2013; 104: 194-199) B reast cancer is the most common malignant disease in women. Its prevalence rate has exhibited a clear increase in China. Furthermore, the mortality rate of breast cancer has risen by 38.9% in the past 20 years.(1) Current prognostic criteria only poorly predict the metastasis risk for an individual breast cancer patient due to a lack of specific biomarkers.(2) Thus, new prognostic biomarkers are urgently needed to identify breast cancer patients and those at the highest risk for developing metastasis.Gene-expression signatures of human primary breast cancers have shown more accurate prediction than current prognostic criteria.(3,4) ubiquitin-like, containing PHD and RING finger domains 1 (UHRF1) is a newly discovered gene reported to have a function in maintaining DNA methylation by helping recruit DNA methyltransferase 1 (DNMT1) to hemimethylated DNA. Kim et al.(5) demonstrated its new role as a transcriptional corepressor in recruitment of histone methyltransferase G9a and other chromatin modifying enzymes to target promoters, and pointed out its dynamic regulation mode in cancer cells. The functional research of UHRF1 have made it a novel diagnostic marker in lung and bladder cancer.(6,7) Ubiquitinlike, containing PHD and RING finger domains 1-induced epigenetic changes, involving DNA methylation, histone modification, chromatin remodeling and recruitment of transcriptional complex on the breast cancer susceptibility gene 1 (BRCA1) promoter, are responsible for BRCA1 silencing in sporadic breast cancer.(8) These findings indicate that UHRF1 might play an important role in cancer development.Cancer patients generally exhibit an increasing amount of circulating DNA that comes from cancer tissues. (9)(10)(11) However, it is difficult to establish a unitary method for de...

show abstract

Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas

Abstract: Quantification of circulating DNA by real-time PCR at diagnosis can identify patients with elevated levels that are associated with disease characteristics indicating aggressive disease and poor prognosis.

Cited by 124 publications

References 22 publications

Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma

Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma

Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis

Diagnostic and prognostic value of plasma and tissue ubiquitin‐like, containing PHD and RING finger domains 1 in breast cancer patients

Contact Info

Product

Resources

About